Clinical Trial Detail

NCT ID NCT03256136
Title A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Massachusetts General Hospital
Indications

non-small cell lung carcinoma

Therapies

Carboplatin + Nivolumab + Pemetrexed

Nivolumab + Ipilimumab

Age Groups: adult senior

Additional content available in CKB BOOST